Second-line combo for advanced liver cancer after HAIC failure
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs—an immunotherapy (TQB2450), a targeted therapy (anlotinib), and a repeat HAIC infusion—for people whose advanced liver cancer has worsened after a first treatment. It may be an option if you've already had HAIC with platinum and are now looking for a new approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced liver cancer (hepatocellular carcinoma) that did not respond to or you could not tolerate your first treatment.
- You have previously received a type of chemotherapy called HAIC that contained a platinum drug.
- You have not had certain other cancers in the last 5 years (except for very low-risk ones like skin cancer).
- Your liver function is good enough (Child-Pugh grade A or B7 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for advanced liver cancer (BCLC stage C): HAIC (chemotherapy directly into the liver), adebrelimab (immunotherapy that helps your immune system fight cancer), and apatinib (a targeted drug that cuts off blood supply to tumors). It may be an option if you have not had any prior systemic (whole-body) therapy for liver cancer.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This Phase 2 trial studies whether delivering an immunotherapy drug directly into the liver’s artery, together with bevacizumab, can shrink advanced hepatocellular carcinoma. You may be considered if prior whole-body (systemic) treatment has not worked and prior local procedures were also not tolerated or failed.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.